In a landmark legal outcome that has sent shockwaves through the UK healthcare sector, Bolton-based medical supplier Medicina Limited and its director, Kenneth Harrison, have been convicted of a series of fraud offences. The convictions conclude a protracted, years-long investigation by the Medicines and Healthcare products Regulatory Agency (MHRA) into the distribution of medical devices bearing fraudulent CE markings.
These devices—specifically enteral feeding pumps and gastrostomy "button" devices—were supplied to National Health Service (NHS) Trusts and other healthcare providers, misleading clinicians into believing the equipment met the rigorous safety and performance standards required for use on vulnerable patients, including critically ill newborns in neonatal intensive care units.
The Core of the Fraud: False Assurances
At the heart of the case is the integrity of the CE marking system. In the UK, as in the European Union, the CE mark serves as a manufacturer’s declaration that a product meets the essential health, safety, and environmental requirements defined by law—specifically the UK Medical Device Regulations 2002 (UK MDR).
The investigation, spearheaded by the MHRA’s Devices Compliance unit, revealed that Medicina Limited systematically supplied equipment that lacked valid certification. By affixing false CE markings, the company provided a "false assurance" to medical professionals. These devices were intended for high-stakes clinical environments, where precision and reliability are matters of life and death. The discovery that these pumps were being used to deliver life-sustaining nutrition directly into the stomachs of premature and sick infants has underscored the profound gravity of the deception.
A Chronology of Deception and Investigation
The road to conviction was long, spanning over a decade of regulatory scrutiny and legal proceedings.
- 2013: The MHRA first identified irregularities and concerns regarding the compliance of certain medical devices manufactured by Medicina Limited. This initial trigger launched an extensive regulatory investigation.
- 2013–2025: Throughout this period, the MHRA gathered evidence regarding the company’s manufacturing processes and their failure to secure valid conformity assessments for their product lines, specifically the P900 enteral feeding pumps.
- June 2025: As the investigation reached its climax, the UK government implemented stricter post-market surveillance requirements, further tightening the regulatory net around non-compliant manufacturers.
- 2026: Following a successful prosecution by the Crown Prosecution Service (CPS) in collaboration with the MHRA, the court found both Medicina Limited and Kenneth Harrison guilty of fraud.
- 23 September 2026: Kenneth Harrison is scheduled for sentencing, a date that will mark a pivotal moment in the accountability of medical device executives in the UK. The sentencing for the corporate entity, Medicina Limited, is currently pending.
Regulatory Standards and the Requirement for Transparency
The UK medical device market relies heavily on a system of self-declaration backed by independent third-party assessments (Notified Bodies). For a device to be legally marketed, it must be registered with the MHRA and comply with the UK MDR 2002.
The Medicina case highlights the vulnerability of this system to bad actors who prioritize profit over patient safety. When a company bypasses the conformity assessment process, they effectively operate outside the reach of safety oversight. This not only puts patients at risk but also undermines the trust that NHS procurement teams place in their supply chain partners.
The removal of these devices from circulation in the UK and select European markets has necessitated a massive logistical undertaking for hospitals to audit their equipment inventories and replace the compromised pumps with verified, safe alternatives.
Official Responses: A Zero-Tolerance Stance
The reaction from regulatory and prosecutorial authorities has been one of stern condemnation, emphasizing that patient safety is non-negotiable.
James Pound, executive director for innovation and compliance at the MHRA, was unequivocal in his statement following the conviction. "This outcome sends a clear message that the MHRA will not hold back when patient safety is at risk," Pound noted. He highlighted that medical devices, particularly those used for the most vulnerable populations, must undergo stringent testing to ensure they do not cause harm.
Sarah Place, a specialist prosecutor from the CPS, provided a blistering assessment of the defendants’ motives. "The actions of Harrison and Medicina Limited were completely dishonest," she stated. "From their fraudulently labelled products, they turned a substantial profit. CPS lawyers worked closely with the MHRA to prosecute this case, and we will continue to bring those who commit fraud to justice."
Broader Implications for Medical Device Regulation
The Medicina scandal serves as a catalyst for a necessary evolution in how the UK and Europe police the medical device landscape. Unlike the pharmaceutical industry, which has benefited from the EU’s Falsified Medicines Directive (FMD)—a robust system for preventing counterfeit drugs from entering the supply chain—the medical device sector has historically lacked a similarly centralized, high-tech monitoring mechanism.
The Shift Toward Enhanced Traceability
The industry is now poised for a significant shift in how devices are identified and tracked. The lack of a "FMD-equivalent" for devices has left a gap that fraudulent actors have been all too ready to exploit. However, the regulatory landscape is changing:
- Post-Market Surveillance: The MHRA’s updated regulations from June 2025 place a greater burden on manufacturers to prove the ongoing safety and efficacy of their products throughout their lifecycle, rather than just at the point of market entry.
- The Role of EUDAMED: In Europe, the implementation of the European Database on Medical Devices (EUDAMED) is being treated as a high-priority initiative. By centralizing the registration and tracking of devices, EUDAMED aims to provide a "single source of truth" that allows regulators to identify discrepancies in real-time.
- Global Harmonization: As the EU works toward full implementation of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) by 2028, the international community is moving toward a more harmonized approach. The goal is to ensure that a device manufactured in one region can be verified for compliance in another, closing the loopholes that allow fraudulent actors to hide in the cracks of disparate regulatory systems.
Lessons Learned for the NHS and Procurement
For the National Health Service, this case serves as a harsh lesson in the necessity of enhanced due diligence. While procurement teams cannot be expected to perform the role of a regulatory body, the Medicina case suggests that the standard vetting process for suppliers must be more rigorous.
The "Yellow Card" scheme in the UK, which allows healthcare professionals and patients to report suspected side effects or defects in medical devices, remains a vital tool. However, the Medicina case suggests that the system requires more than just reactive reporting; it requires proactive, data-driven verification of CE certification at the procurement level.
Conclusion: Restoring Confidence
The conviction of Medicina Limited and Kenneth Harrison is a victory for public health, but it is also a sober reminder of the fragility of medical supply chains. As the industry moves toward a future defined by the transparency of databases like EUDAMED and the increased oversight of the MHRA, the focus must remain on the patient.
The "false assurance" provided by Medicina was not just a violation of law; it was a violation of the fundamental duty of care owed to every patient who relies on medical technology to survive. As the court prepares to deliver its final sentencing, the medical device industry faces a new era of accountability—one where the cost of fraud is no longer just a financial penalty, but the complete loss of license to operate within the healthcare ecosystem.
For the families of the newborns who were treated with the compromised P900 pumps, the legal proceedings provide a sense of justice, but the incident will undoubtedly leave a lasting legacy on how the UK manages the safety of the devices that keep its most vulnerable citizens alive. Moving forward, the mandate for manufacturers is clear: compliance is not a hurdle to be cleared, but the bedrock of medical practice.
About the Author
